NCT01583036View on ClinicalTrials.gov

An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 16, 2012

Primary Completion Date

April 17, 2012

Study Completion Date

April 17, 2012

Conditions

Epilepsy

Interventions

DRUG

Digoxin Alone

Single administration of digoxin 0.25mg

DRUG

Digoxin + Retigabine

Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.

Trial Locations (1)

21225

GSK Investigational Site, Baltimore